Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. History of insulin-dependent dabetes mellitus
3. Autoimmune origin of human type 1 diabetes
4. Islet cells autoantibodies
5. Multiplicity of autoantigens in IDDM
6. An experimental model - NOD mouse
7. Natural history of type 1 diabetes
8. The transfer of diabetes
9. Insulitis transfer with purified T-cell subsets
10. Regulatory T-cells in a diabetes co-transfer model
11. Prevention of diabetes transfer by TREG
12. Objectives of immunotherapy in IDDM
13. Three features of immunotherapy of diabetes
14. Trial of CsA in recently diagnosted IDDM
15. Immunosuppression vs. immune tolerance
16. Back to NOD mouse model
17. The CD3 molecular complex
18. Diabetes remission in CD3 antibody-treated mice
19. CD3 antibody-treated NOD mice
20. Increased T-cells in anti-CD3 treated mice
21. Effect of anti-TGFbeta on remissions
22. Antibodies used in clinical trials
23. Non-mitogenic CD3 antibody treatments
24. The ChAglyCD3 antibody
25. Efficacy measurements
26. ChAglyCD3 antibody treatment: results
27. Insulin needs at 18 months
28. Proportions of circulating lymphocytes
29. EBV reactivation
30. Representative data from three patients
31. CD8 T-cell response to EBV lytic antigens
32. Conclusions
33. Acknowledgments

Topics Covered

• The history of IDDM
• Autoimmune origin of human type 1 diabetes
• Natural history and pathophysiology of type 1 diabetes
• The role of regulatory T-cells in the control of type 1 diabetes
• Objectives of immunotherapy in insulin-dependent diabetes mellitus
• The use of immunosuppressants in type 1 diabetes
• The use of tolerance promoting monoclonal antibodies in type 1 diabetes: the case of CD3 antibodies

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Cardiovascular & Metabolic
• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Reviewed on June 13, 2019
• Archived on August 31, 2020

Financial Disclosures

• Prof. Lucienne Chatenoud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.